Integer Holdings Corp Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $1.8B+7.4% YoYTTM through 3 Jul 2026
Net Income $128.4M+7.1% YoYTTM through 3 Jul 2026
Free Cash Flow $112MTTM through 3 Jul 2026
Margins
| Current | |
|---|---|
| Gross Margin | 27.0% |
| EBITDA Margin | 17.2% |
| Operating Margin | 11.9% |
| Net Margin | 7.0% |
Returns
5.9%ROE
3.0%ROA
4.4%ROIC
Balance Sheet Health
Debt / Equity0.68x
Current Ratio3.73x
Net Debt$1.2B
Cash & Equivalents$21.4M
Quality Metrics
Altman Z-Score2.85
Piotroski F-Score7 / 9
FCF Margin6.1%
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $1.9B
Diluted EPS$3.65TTMFY2025: $2.89
Dividend
No dividend
Capital Allocation
Capex Intensity5.1%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Cardio & Vascular | $1.1B | +17.0% | View detailsExpect flat to down low single digits in 2026 primarily due to a decline from two previously communicated new Electrophysiology products. |
| Cardiac Rhythm Management & Neuromodulation | $668.8M | +1.0% | View detailsExpect flat to up low single digits in 2026, inclusive of a decline from one previously communicated new Neuromodulation product. |
| Other Markets | $77.8M | -27.0% | View detailsPortable Medical exit is expected to be completed by the end of 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.